Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition

On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL).

The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism.

Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, 2025.

Also Read: Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

The transaction represents a total equity value of approximately $1.5 billion. Alcon intends to ...